<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">101505086</journal-id>
<journal-id journal-id-type="pubmed-jr-id">36963</journal-id>
<journal-id journal-id-type="nlm-ta">Sci Transl Med</journal-id>
<journal-id journal-id-type="iso-abbrev">Sci Transl Med</journal-id>
<journal-title-group>
<journal-title>Science translational medicine</journal-title>
</journal-title-group>
<issn pub-type="ppub">1946-6234</issn>
<issn pub-type="epub">1946-6242</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">27122614</article-id>
<article-id pub-id-type="pmc">4995450</article-id>
<article-id pub-id-type="doi">10.1126/scitranslmed.aad9370</article-id>
<article-id pub-id-type="manuscript">NIHMS810708</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>MDM2 Inhibition rescues neurogenic and cognitive deficits in fragile X mice</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Li</surname>
<given-names>Yue</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Stockton</surname>
<given-names>Michael E.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bhuiyan</surname>
<given-names>Ismat</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Eisinger</surname>
<given-names>Brian E.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gao</surname>
<given-names>Yu</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Miller</surname>
<given-names>Jessica L.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bhattacharyya</surname>
<given-names>Anita</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zhao</surname>
<given-names>Xinyu</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
</contrib-group>
<aff id="A1"><label>1</label>Waisman Center, University of Wisconsin-Madison, Madison, WI 53705, USA</aff>
<aff id="A2"><label>2</label>Department of Neuroscience, University of Wisconsin-Madison, Madison, WI 53705, USA</aff>
<author-notes>
<corresp id="cor1">Corresponding author: Xinyu Zhao (Waisman Center and Department of Neuroscience, University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI 53705, USA; Phone: (608) 263-9906; <email>Xinyu.zhao@wisc.edu</email></corresp>
<fn fn-type="COI-statement" id="FN3">
<p id="P58"><bold>Competing interests:</bold> The authors declare no conflict of interest.</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>19</day>
<month>8</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="ppub">
<day>27</day>
<month>4</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>27</day>
<month>10</month>
<year>2016</year>
</pub-date>
<volume>8</volume>
<issue>336</issue>
<fpage>336ra61</fpage>
<lpage>336ra61</lpage>
<!--elocation-id from pubmed: 10.1126/scitranslmed.aad9370-->
<abstract>
<p id="P1">Fragile X syndrome, the most common form of inherited intellectual disability, is caused most often by a lack of fragile X mental retardation protein (FMRP). However, the mechanism remains unclear and effective treatment is lacking. Here we show that a loss of FMRP leads to activation of adult neural stem cells (NSCs) and a subsequent reduction in neuronal production. We identified ubiquitin ligase MDM2 as a target of FMRP. FMRP regulates <italic>Mdm2</italic> mRNA stability, and loss of FMRP results in elevated mRNA and MDM2 protein levels. We further found that increased MDM2 levels lead to reduced P53 in NSCs, which alters NSC proliferation and differentiation. Treatment with Nutlin-3, a small molecule undergoing clinical trials for cancer, specifically inhibits MDM2 and P53 interaction, and rescues the neurogenic and cognitive deficits in FMRP-deficient mice. Our data unveil a regulatory role for FMRP and a potential new treatment for fragile X syndrome.</p>
</abstract>
</article-meta>
</front>
</article>
</pmc-articleset>